Is Protagenic Therapeutics Stock a Good Investment?
Protagenic Therapeutics Investment Advice | PTIXW |
Not Rated
Examine Protagenic Therapeutics Stock
Researching Protagenic Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if Protagenic Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Protagenic Therapeutics' research are outlined below:
| Protagenic Therapeutics is not yet fully synchronised with the market data | |
| Protagenic Therapeutics is way too risky over 90 days horizon | |
| Protagenic Therapeutics has some characteristics of a very speculative penny stock | |
| Protagenic Therapeutics appears to be risky and price may revert if volatility continues | |
| Protagenic Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics has accumulated about 671.09 K in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Protagenic Therapeutics has a frail financial position based on the latest SEC disclosures |
Protagenic Therapeutics Quarterly Good Will |
|
Protagenic Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.21) | |
| Return On Capital Employed | (1.23) | (1.17) | |
| Return On Assets | (1.16) | (1.21) | |
| Return On Equity | (1.36) | (1.30) |
Determining Protagenic Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Protagenic Therapeutics is a good buy. For example, gross profit margin measures Protagenic Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Protagenic Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Protagenic Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Protagenic Therapeutics. Check Protagenic Therapeutics' Beneish M Score to see the likelihood of Protagenic Therapeutics' management manipulating its earnings.
Evaluate Protagenic Therapeutics' management efficiency
The company has return on total asset (ROA) of (0.9017) % which means that it has lost $0.9017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.0636) %, meaning that it generated substantial loss on money invested by shareholders. Protagenic Therapeutics' management efficiency ratios could be used to measure how well Protagenic Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.21 in 2024. Return On Capital Employed is likely to climb to -1.17 in 2024. At this time, Protagenic Therapeutics' Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to climb to about 6.4 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 117.2 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.84 | 0.80 | |
| Tangible Book Value Per Share | 0.84 | 0.80 | |
| Enterprise Value Over EBITDA | (0.67) | (0.64) | |
| Price Book Value Ratio | 1.17 | 1.11 | |
| Enterprise Value Multiple | (0.67) | (0.64) | |
| Price Fair Value | 1.17 | 1.11 | |
| Enterprise Value | 3.5 M | 3.3 M |
The management strategies employed by Protagenic Therapeutics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 0.25 |
Protagenic Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protagenic Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protagenic Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protagenic Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Musci Raymond over a month ago Acquisition by Musci Raymond of 1758 shares of Protagenic Therapeutics at 2.09 subject to Rule 16b-3 | ||
Musci Raymond over a month ago Acquisition by Musci Raymond of 569 shares of Protagenic Therapeutics at 2.07 subject to Rule 16b-3 | ||
Ekizian Gregory over two months ago Disposition of 75000 shares by Ekizian Gregory of Protagenic Therapeutics at 1.0 subject to Rule 16b-3 | ||
Brilliant Digital Entertainment Inc over three months ago Acquisition by Brilliant Digital Entertainment Inc of 758621 shares of Protagenic Therapeutics at 2.9 subject to Rule 16b-3 | ||
Musci Raymond over six months ago Acquisition by Musci Raymond of tradable shares of Protagenic Therapeutics at 2.0 subject to Rule 16b-3 | ||
Robert Stein over six months ago Acquisition by Robert Stein of 200000 shares of Protagenic Therapeutics at 1.75 subject to Rule 16b-3 | ||
Garo Armen over six months ago Acquisition by Garo Armen of 500000 shares of Protagenic Therapeutics at 1.25 subject to Rule 16b-3 |
Understand Protagenic Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Protagenic Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0664 | |||
| Market Risk Adjusted Performance | (0.55) | |||
| Mean Deviation | 18.71 | |||
| Semi Deviation | 18.23 | |||
| Downside Deviation | 26.12 | |||
| Coefficient Of Variation | 1351.99 | |||
| Standard Deviation | 30.1 | |||
| Variance | 905.83 | |||
| Information Ratio | 0.0698 | |||
| Jensen Alpha | 2.67 | |||
| Total Risk Alpha | (2.32) | |||
| Sortino Ratio | 0.0804 | |||
| Treynor Ratio | (0.56) | |||
| Maximum Drawdown | 159.98 | |||
| Value At Risk | (41.67) | |||
| Potential Upside | 63.74 | |||
| Downside Variance | 682.28 | |||
| Semi Variance | 332.22 | |||
| Expected Short fall | (40.64) | |||
| Skewness | 1.21 | |||
| Kurtosis | 2.48 |
| Risk Adjusted Performance | 0.0664 | |||
| Market Risk Adjusted Performance | (0.55) | |||
| Mean Deviation | 18.71 | |||
| Semi Deviation | 18.23 | |||
| Downside Deviation | 26.12 | |||
| Coefficient Of Variation | 1351.99 | |||
| Standard Deviation | 30.1 | |||
| Variance | 905.83 | |||
| Information Ratio | 0.0698 | |||
| Jensen Alpha | 2.67 | |||
| Total Risk Alpha | (2.32) | |||
| Sortino Ratio | 0.0804 | |||
| Treynor Ratio | (0.56) | |||
| Maximum Drawdown | 159.98 | |||
| Value At Risk | (41.67) | |||
| Potential Upside | 63.74 | |||
| Downside Variance | 682.28 | |||
| Semi Variance | 332.22 | |||
| Expected Short fall | (40.64) | |||
| Skewness | 1.21 | |||
| Kurtosis | 2.48 |
Consider Protagenic Therapeutics' intraday indicators
Protagenic Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Protagenic Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.44 | |||
| Daily Balance Of Power | 1.015873 | |||
| Rate Of Daily Change | 1.8 | |||
| Day Median Price | 0.0113 | |||
| Day Typical Price | 0.0123 | |||
| Market Facilitation Index | 0.0063 | |||
| Price Action Indicator | 0.0064 | |||
| Period Momentum Indicator | 0.0064 |
Protagenic Stock media impact
Far too much social signal, news, headlines, and media speculation about Protagenic Therapeutics that are available to investors today. That information is available publicly through Protagenic media outlets and privately through word of mouth or via Protagenic internal channels. However, regardless of the origin, that massive amount of Protagenic data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Protagenic Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protagenic Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protagenic Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protagenic Therapeutics alpha.
Protagenic Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Protagenic Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Protagenic Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Protagenic Therapeutics stock to make a market-neutral strategy. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Protagenic Therapeutics Corporate Management
| Robert Stein | Chief Director | Profile | |
| CFA MD | CFO Sec | Profile | |
| Garo Armen | CoFounder Chairman | Profile | |
| David Lovejoy | Scientific Officer | Profile | |
| Andrew Slee | Chief Officer | Profile |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.